SS
MDGL icon

SBI Securities’s Madrigal Pharmaceuticals MDGL Stock Holding History

SBI Securities’s Portfolio MDGL Stock Details MDGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$9.13K Sell
17
-44
-72% -$22.5K ﹤0.01% 1881
2026
Q1 		$31.9K Hold
61
– – ﹤0.01% 1278
2025
Q4 		$35.5K Sell
61
-12
-16% -$6.13K ﹤0.01% 1225
2025
Q3 		$33.5K Sell
73
-2
-3% -$746 ﹤0.01% 1249
2025
Q2 		$22.7K Buy
75
+5
+7% +$1.49K ﹤0.01% 1368
2025
Q1 		$23.2K Hold
70
– – ﹤0.01% 1270
2024
Q4 		$21.6K Buy
+70
New +$19.7K ﹤0.01% 1313

Other funds holding MDGL

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
PC
Paulson & Co New York $2.58B AUM 68.51% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

SBI Securities's MDGL Position: Q2 2026 in Review

SBI Securities reduced its Madrigal Pharmaceuticals (MDGL) stake by 72% in Q2 2026, selling an estimated $22.5K and leaving 17 shares worth $9.13K. The position accounts for ﹤0.01% of the portfolio, ranked #1881.

SBI Securities first reported a position in MDGL in Q4 2024 and has held it in 7 quarters since. The position peaked at $35.5K in Q4 2025. 413 funds tracked by Wall St. Rank hold MDGL as of Q2 2026.

  • SBI Securities held 17 shares of Madrigal Pharmaceuticals worth $9.13K as of Q2 2026.
  • SBI Securities sold 44 Madrigal Pharmaceuticals shares in Q2 2026, an estimated $22.5K.
  • Madrigal Pharmaceuticals made up ﹤0.01% of SBI Securities's portfolio in Q2 2026, its #1881 holding.
  • SBI Securities first reported a position in Madrigal Pharmaceuticals in Q4 2024 and has held it in 7 quarters since.
  • SBI Securities's Madrigal Pharmaceuticals position peaked at $35.5K in Q4 2025.
  • 413 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q2 2026.

Based on SBI Securities's 13F filing for Q2 2026, filed 23 Jul 2026.